IE
ACRS icon

Israel Englander’s Aclaris Therapeutics ACRS Stock Holding History

Israel Englander’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100,000
Closed -$685K – 6019
2023
Q3 		$685K Buy
+100,000
New +$855K ﹤0.01% 4457

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Israel Englander's ACRS Position: Q2 2026 in Review

Israel Englander reduced its Aclaris Therapeutics (ACRS) stake by 31% in Q2 2026, selling an estimated $1.04M and leaving 523,895 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #3551.

Israel Englander first reported a position in ACRS in Q1 2017 and has held it in 33 quarters since. The position peaked at $13.5M in Q3 2023. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Israel Englander held 523,895 shares of Aclaris Therapeutics worth $2.77M as of Q2 2026.
  • Israel Englander sold 232,232 Aclaris Therapeutics shares in Q2 2026, an estimated $1.04M.
  • Aclaris Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3551 holding.
  • Israel Englander first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 33 quarters since.
  • Israel Englander's Aclaris Therapeutics position peaked at $13.5M in Q3 2023.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.